BR9908401A - Derivado de ácido carboxìlico, preparação farmacêutica para uso oral, parenteral ou intraperitoneal, usos de um derivado de ácido carboxìlico e de compostos, e, fragmento estrutural - Google Patents

Derivado de ácido carboxìlico, preparação farmacêutica para uso oral, parenteral ou intraperitoneal, usos de um derivado de ácido carboxìlico e de compostos, e, fragmento estrutural

Info

Publication number
BR9908401A
BR9908401A BR9908401-5A BR9908401A BR9908401A BR 9908401 A BR9908401 A BR 9908401A BR 9908401 A BR9908401 A BR 9908401A BR 9908401 A BR9908401 A BR 9908401A
Authority
BR
Brazil
Prior art keywords
carboxylic acid
acid derivative
compounds
oral
pharmaceutical preparation
Prior art date
Application number
BR9908401-5A
Other languages
English (en)
Inventor
Wilhelm Amberg
Rolf Jansen
Dagmar Klinge
Harmut Riechers
Stefan Hergenr Der
Manfred Raschack
Liliane Unger
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of BR9908401A publication Critical patent/BR9908401A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"DERIVADO DE áCIDO CARBOXìLICO, PREPARAçãO FARMACêUTICA PARA USO ORAL, PARENTERAL OU INTRAPERITONEAL, USOS DE UM DERIVADO DE áCIDO CARBOXìLICO E DE COMPOSTOS, E, FRAGMENTO ESTRUTURAL" Derivados de ácido carboxílico em que R¹-R^ 6^, Q, W, X, Y e Z têm os significados estabelecidos no relatório descritivo e sua preparação são descritos. Os novos compostos são adequados para controlar doenças.
BR9908401-5A 1998-03-04 1999-02-25 Derivado de ácido carboxìlico, preparação farmacêutica para uso oral, parenteral ou intraperitoneal, usos de um derivado de ácido carboxìlico e de compostos, e, fragmento estrutural BR9908401A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19809144A DE19809144A1 (de) 1998-03-04 1998-03-04 Neue unsymmetrisch substituierte Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶LAMBDA¶/ET¶B¶-Rezeptorantagonisten
PCT/EP1999/001208 WO1999044998A1 (de) 1998-03-04 1999-02-25 Neue unsymmetrisch substituierte carbonsäurederivate, ihre herstellung und verwendung als gemischte eta/etb-rezeptorantagonisten

Publications (1)

Publication Number Publication Date
BR9908401A true BR9908401A (pt) 2000-10-31

Family

ID=7859627

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9908401-5A BR9908401A (pt) 1998-03-04 1999-02-25 Derivado de ácido carboxìlico, preparação farmacêutica para uso oral, parenteral ou intraperitoneal, usos de um derivado de ácido carboxìlico e de compostos, e, fragmento estrutural

Country Status (22)

Country Link
EP (1) EP1060167A1 (pt)
JP (1) JP2002505324A (pt)
KR (1) KR20010041537A (pt)
CN (1) CN1292782A (pt)
AR (1) AR020317A1 (pt)
AU (1) AU2624799A (pt)
BG (1) BG104754A (pt)
BR (1) BR9908401A (pt)
CA (1) CA2322541A1 (pt)
CO (1) CO5080805A1 (pt)
DE (1) DE19809144A1 (pt)
HR (1) HRP20000650A2 (pt)
HU (1) HUP0101173A3 (pt)
ID (1) ID26183A (pt)
IL (1) IL137537A0 (pt)
NO (1) NO20004351L (pt)
PL (1) PL342806A1 (pt)
SK (1) SK11752000A3 (pt)
TR (1) TR200002545T2 (pt)
TW (1) TW509676B (pt)
WO (1) WO1999044998A1 (pt)
ZA (1) ZA991738B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19924892A1 (de) * 1999-06-01 2000-12-07 Basf Ag Neue Carbonsäurederivate mit arylsubstituierten Stickstoffheterocyclen, ihre Herstellung und Verwendung als Endothelin Rezeptorantagonisten
JP2003511356A (ja) * 1999-10-06 2003-03-25 ビーエーエスエフ アクチェンゲゼルシャフト 併用療法のためのサイトカイン媒介性シグナル伝達経路のモジュレーター及びインテグリンαｖβ３受容体アンタゴニスト

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4411225A1 (de) * 1994-03-31 1995-10-05 Basf Ag Verwendung von Carbonsäurederivaten als Arzneimittel
DE19636046A1 (de) * 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten

Also Published As

Publication number Publication date
CN1292782A (zh) 2001-04-25
BG104754A (en) 2001-05-31
HUP0101173A2 (hu) 2002-03-28
DE19809144A1 (de) 1999-09-09
WO1999044998A1 (de) 1999-09-10
ZA991738B (en) 2000-10-11
TW509676B (en) 2002-11-11
JP2002505324A (ja) 2002-02-19
HRP20000650A2 (en) 2001-06-30
NO20004351D0 (no) 2000-09-01
PL342806A1 (en) 2001-07-02
EP1060167A1 (de) 2000-12-20
ID26183A (id) 2000-12-07
TR200002545T2 (tr) 2000-11-21
HUP0101173A3 (en) 2002-05-28
SK11752000A3 (sk) 2001-05-10
NO20004351L (no) 2000-09-01
CA2322541A1 (en) 1999-09-10
AR020317A1 (es) 2002-05-08
KR20010041537A (ko) 2001-05-25
CO5080805A1 (es) 2001-09-25
IL137537A0 (en) 2001-07-24
AU2624799A (en) 1999-09-20

Similar Documents

Publication Publication Date Title
FI870219A0 (fi) Hypoglykemiska tiazolidindioner.
BR9907788A (pt) Agentes antiinflamatórios seletivos paraglicocorticóides
DK0914119T3 (da) Fremgangsmåde til fremstilling af faste orale dosisformer af valsartan
NO174239C (no) Fremgangsmåte for fremstilling av et oralt, farmasöytisk preparat
BR0109703A (pt) Derivados de piperazina
NO981800D0 (no) FremgangsmÕte for fremstilling av 1,1,1,3,3-pentafluorpentan
ATE94869T1 (de) Diphenylheteroalkylderivate, ihre herstellung und daraus hergestellte arzneimittel und kosmetika.
ATE255117T1 (de) Aminophosphonsäure-derivate als arzneimittel
BR9711311B1 (pt) derivado de 1,2,3,4-tetrahidroquinolina, composiÇço farmaceutica, uso de um derivado de 1,2,3,4-tetrahidroquinolina, e, processo para a preparaÇço de compostos.
SK1452000A3 (en) Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists
NO983864L (no) Morfin- og diamorfinsalter av anioniske, ikke-narkotiske analgetika av den substituerte karboksyltypen
SE8904298D0 (sv) New compounds
NO986086D0 (no) FremgangsmÕte for fremstilling av 17-estere av 9<alfa>,21-dihalo-pregnan-11
NO20002174D0 (no) FremgangsmÕte for fremstilling av tiazolidindion-derivater
NO175976C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 4-(1,6-dihydro-6-okso-pyridazinyl-3-oksy)-3-kromanolderivater
TR200000697T2 (tr) İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları.
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
ATE400563T1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
NO983860L (no) Nye triazolopuriner, fremgangsmÕte for deres fremstilling og deres anvendelse som legemidler
NO993949D0 (no) FremgangsmÕte for fremstilling av substituert tiazolidindion
BR9908401A (pt) Derivado de ácido carboxìlico, preparação farmacêutica para uso oral, parenteral ou intraperitoneal, usos de um derivado de ácido carboxìlico e de compostos, e, fragmento estrutural
NO975680D0 (no) Oralt, farmasöytisk preparat av piperidinoalkanol-forbindelser i opplösningsform
DK0735043T3 (da) Fremgangsmåde til fremstilling af 2-substitueret 3,3-difluorfuran
PT1025101E (pt) Derivados de nafto-imidazo¬1,2-a|piridina sua preparacao e uso no tratamento de perturbacoes do sistema nervoso central
ATE215941T1 (de) Isoflavonderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: ABBOTT GMBH & CO. KG (DE)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTA A 5O, 6O, 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.